

This is an author-submitted, peer-reviewed version of a manuscript that has been accepted for publication in the *European Respiratory Journal*, prior to copy-editing, formatting and typesetting. This version of the manuscript may not be duplicated or reproduced without prior permission from the European Respiratory Society. The publisher is not responsible or liable for any errors or omissions in this version of the manuscript or in any version derived from it by any other parties. The final, copy-edited, published article, which is the version of record, is available without a subscription 18 months after the date of issue publication.

Invisibility of breathlessness in clinical consultations: a cross-sectional, national online survey

Slavica Kochovska ^{1,2}

Sungwon Chang ²

Diana Ferreira ¹

Vanessa N. Brunelli ³

Tim Lockett ²

Lucy Morgan ⁴

Miriam J. Johnson ⁵

Magnus Ekström ⁶

David C. Currow ¹

¹Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, New South Wales, Australia

²IMPACCT, Faculty of Health, University of Technology Sydney, New South Wales, Australia

³Centre for Healthcare Transformation, Faculty of Health, Queensland University of Technology, Kelvin Grove, Queensland, Australia

⁴Concord Hospital, Department of Respiratory Medicine, Concord Repatriation General Hospital, Concord, New South Wales, Australia

⁵Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, Hull, United Kingdom

⁶Lund University Faculty of Medicine, Department of Clinical Sciences Lund, Respiratory Medicine and Allergology, Lund, Sweden

Corresponding author:

Slavica Kochovska, PhD

Faculty of Science, Medicine and Health

University of Wollongong

Wollongong, NSW 2522, Australia

Email: slavica.kochovska@uow.edu.au

Document details:

Word count (excluding abstract, references, tables and figures): 1219

References: 17

Tables and figures: 1

Keywords: breathlessness, clinical consultations, clinical history taking, patient-clinician communication, cross-sectional survey

Take home message:

Breathlessness is invisible in patient-clinician consultations. Improving clinical history taking is critical to help identify more consistently the presence and impact of breathlessness, especially for people living long-term with this disabling symptom.

Author's Copy

To the Editor

Breathlessness diminishes the physical, mental and social wellbeing of people living long-term with this disabling symptom [1]. Identifying its impacts on patients and their families helps to inform appropriate non-pharmacological and pharmacological management [2, 3]. A randomised controlled trial suggests that clinicians are less likely to identify or manage chronic breathlessness than chronic pain [4]. Previous population studies estimate 9.5% of adults experience breathlessness [5], with 1 in 100 individuals being seriously impacted daily [6]. We conducted a population study aimed at identifying the proportion of people with breathlessness who report this symptom in clinical consultations. If discussed, we explored whether patients or clinicians (physicians; nurses) initiated the conversation and, if not discussed, whether patients would welcome such discussions.

An Australian cross-sectional, online survey using the Qualtrics platform (Qualtrics, Utah, USA) was undertaken (12 July-2 August, 2021) to recruit adults (≥ 18 years) representative of the Australian 2016 census population by age, sex, state/territory of residence and rurality [7]. Participants were invited by Qualtrics through its database of >800,000 registered panel members. Recruitment quotas were set for combinations of all four demographic parameters.

The survey was piloted with members of the Improving Palliative, Aged and Chronic Care through Clinical Research and Translation (IMPACCT) Consumer Advisory Group (University of Technology Sydney) and 110 Qualtrics' panellists before general recruitment. Panel members provided initial informed consent when joining Qualtrics' panel. A Participant Information Sheet was provided before obtaining additional informed consent for this survey. Approval was obtained from the Human Research Ethics Committee (University of Technology Sydney; UTS HREC ETH20-5114).

Participants' self-reported data included: age, sex, state/territory of residence, postcode (to code rurality using the Australian Statistical Geography Standards [8]), height/weight (to estimate body mass index (BMI)), and smoking status. The presence and severity of breathlessness was assessed using the modified Medical Research Council (mMRC)

breathlessness scale (0-4) [9]. Higher scores indicate decreasing physical exertion before breathlessness supervenes. Analyses compared mMRC 2 with mMRC 3-4. The duration (years/months) and perceived primary cause (multiple-choice from a range of health conditions) of breathlessness were sought. Respondents with breathlessness were asked whether this had ever been discussed in clinical consultations; if so, who initiated the discussion (patient or clinician); and if not, whether they would welcome such a discussion. (Figure 1)

Author's Copy




Figure 1. Survey questions and main findings. *No significant difference by intensity of breathlessness.

Demographics were described. Differences between those who did and did not initiate conversations (for both patients and clinicians), including preferences, were assessed using chi-square tests, t-tests or Mann Whitney tests as appropriate. Binary and multinomial logistic regression assessed the predictors for preferences regarding breathlessness discussions. No data were imputed. Analyses used Excel (Microsoft Office 16) and Statistical Package for the Social Sciences (SPSS) software, V28.0 (IBM Corporation, Armonk, NY; 2016). A p-value of <0.05 was considered statistically significant.

Of 10,033 survey respondents, 1,106 (11.0%) reported mMRC ≥ 2 for whom: mean age was 43.4 years; 53.4% (n=588) were female; most lived in metropolitan areas (74.7%; n=825); 60.7% (n=671) had a history of smoking; and 49.0% (n=423) attributed their breathlessness to a lung condition. Median breathlessness duration was 3.5 years. BMI was available for 80% of respondents, of whom 60.2% (n=492) reported being overweight/obese/very obese.

Of those with breathlessness, 69.1% (764/1,106) indicated that they initiated discussions about their breathlessness. (Figure 1) For 85.1% (291/342) of those who did *not* raise the issue themselves, clinicians did not raise the topic of breathlessness either (hereon '*invisible breathlessness*'). Of those with *invisible breathlessness*, 53.6% (156/291) indicated they would have welcomed a conversation about it. Breathlessness remained completely unexplored for 24% (72/300) of people with severe breathlessness (mMRC 3-4), of whom 45.8% (33/72) would have welcomed such discussions.

There was no significant association between breathlessness intensity and initiating conversations about breathlessness nor preferences for having such discussions. (Figure 1) Older males were more likely to initiate a conversation, yet less likely to be asked about their breathlessness by clinicians. Breathlessness duration and a history of smoking were predictors for patient- but not clinician-initiated conversations. Clinicians were less likely to discuss breathlessness with patients who are overweight, yet those patients were more likely to welcome such a discussion. In bivariate analyses, age was the only factor in driving preferences for having discussions, and remained as such in multivariate regression when sex, smoking and level of breathlessness were included.

The survey found that 26.3% of people with mMRC ≥ 2 lived with unreported breathlessness, which is similar to a UK population online survey where 29% of people with mMRC ≥ 2 had not sought medical advice for their breathlessness [10].

The key findings are three-fold. Firstly, this study found that breathlessness is often invisible in routine clinical consultations because many patients and clinicians fail to raise the topic, at any time in the past. Specifically, 1 in 2 people with breathlessness and 1 in 4 people with severe breathlessness (i.e. housebound or unable to self-care due to breathlessness) live with the symptom and its associated impact undetected, generating unmet needs.

Secondly, clinicians rarely initiated conversations about breathlessness unless prompted by patients. Although empowering patients to raise the topic with their treating clinician and advocate for their needs is important, identifying breathlessness is a skill in clinicians' history taking and should be implemented routinely. Providing clinicians with a more optimal screening question to identify the presence, severity and impact of breathlessness may be *the* critical first step in initiating a conversation about patients' unmet needs. Such systematic inquiry would facilitate better symptom management, aligned with people's priorities.

Thirdly, breathlessness intensity did not drive these conversations. As people progressively reduce or cease their everyday activities to self-manage their worsening breathlessness, there is a risk that this modified lifestyle becomes their "new normal", whilst affecting the very basic aspects of their personhood. As effects can be experienced for years with progressive deconditioning, clinicians must actively elicit the impact of breathlessness across the symptom's trajectory to help prevent this vicious cycle.

This study shows that breathlessness remains surprisingly invisible within the health system because patients and clinicians alike are reluctant to raise the topic during clinical encounters. Patients may have normalised their breathlessness as expected [11], adjusted their lives to minimise/avoid it [12] or feel stigmatised [13]. Clinicians may underestimate its impact [14] or feel constrained in how to constructively address it [15]. Future research should explore the barriers to communication to better understand the reasons that drive

hesitancy and avoidance in discussing this debilitating symptom in routine practice. Incorporating effective symptom screening, together with education and resources for implementing evidence-based therapies, would enable better long-term symptom management.

This study included a large, nationally representative community sample (standardised to the national census), with reported rates of breathlessness similar to other general adult population prevalence estimates [6]. Although the online delivery may have limited the survey's uptake to those with internet capabilities or digital literacy, it may have positively influenced participation of people with severely limited physical function. It also facilitated recruitment independently of health service contact thus potentially capturing people who are otherwise invisible to it.

Clinicians must actively explore long-term breathlessness because one in two patients with this do not talk about it during routine clinical encounters. Addressing long-term breathlessness proactively, systematically and empathically is a human right that patients should expect to be addressed by competent, caring clinicians [16, 17]. As clinicians rarely initiate breathlessness conversations unless prompted by patients, clinical history taking should be refined with a more effective symptom screening question designed specifically to identify the presence, severity and impact of breathlessness.

Acknowledgements

The authors thank the participants who gave their time to respond to the survey. We thank Qualtrics for facilitating this project especially Daniel Chong, Sujit Singh, Rebecca Toll, Andy Rohner and Matt Lee. We are grateful to Ms. Debbie Marriott for her untiring support in preparing the manuscript for publication and facilitating team meetings for the duration of the project.

Data availability

The questionnaire used in this study is in the public domain and can be accessed at <https://osf.io/fhxkc>

Support statement

This study was supported by a University of Technology Sydney Faculty of Health Early Career Researcher Seed Grant (S. Kochovska) and discretionary funds held by the academic teams involved in the collection and analyses of these data.

Conflict of interest

DCC is an unpaid member of an advisory board for Helsinn Pharmaceuticals and Specialist Therapeutics, and has consulted to, and received intellectual property payments from Mayne Pharma. The other authors declare no competing interests.

Author contributions

Conception and design: SK, DCC; data collection: SK, DCC; data analyses: SK, SC, DCC; drafting the article: SK; revision for important intellectual content and final approval of the version to be published: all authors.

References

1. Johnson MJ, Yorke J, Hansen-Flaschen J, et al., Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness. *Eur Respir J*, 2017. **49**(5): 1602277.
2. Booth S, Moosavi SH, and Higginson IJ, The etiology and management of intractable breathlessness in patients with advanced cancer: A systematic review of pharmacological therapy. *Nat Rev Clin Oncol*, 2008. **5**(2): 90-100.
3. Ekström MP, Abernethy AP, and Currow DC, The management of chronic breathlessness in patients with advanced and terminal illness. *BMJ*, 2015. **349**: g7617.
4. Ahmadi Z, Sandberg J, Shannon-Honson A, et al., Is Chronic Breathlessness Less Recognized and Treated Compared with Chronic Pain?: A Case-Based Randomised Controlled Trial. *Eur Respir J*, 2018: 1800887.
5. Currow DC, Plummer JL, Crockett A, et al., A community population survey of prevalence and severity of dyspnea in adults. *J Pain Symptom Manage*, 2009. **38**(4): 533-545.
6. Poulos LM, Ampon RD, Currow DC, et al., Prevalence and burden of breathlessness in Australian adults: The National Breathlessness Survey – a cross-sectional web-based population survey. *Respirology*, 2021. **26**(8): 768-775.
7. Australian Bureau of Statistics (ABS). 2016 Census QuickStats: Australian Bureau of Statistics. 2016 [accessed 2020 16 March]; Available from: http://quickstats.censusdata.abs.gov.au/census_services/getproduct/census/2016/quickstat/036
8. Australian Bureau of Statistics (ABS). Australian Statistical Geography Standard (ASGS). [accessed 2022 20 June]; Available from: [https://www.abs.gov.au/websitedbs/D3310114.nsf/home/Australian+Statistical+Geography+Standard+\(ASGS\)](https://www.abs.gov.au/websitedbs/D3310114.nsf/home/Australian+Statistical+Geography+Standard+(ASGS))
9. Bestall J, Paul E, Garrod R, et al., Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. *Thorax*, 1999. **54**(7): 581-586.
10. Elbehairy AF, Quint JK, Rogers J, et al., Patterns of breathlessness and associated consulting behaviour: results of an online survey. *Thorax*, 2019. **74**(8): 814-817.

11. Brindle L, Pope C, Corner J, et al., Eliciting symptoms interpreted as normal by patients with early-stage lung cancer: could GP elicitation of normalised symptoms reduce delay in diagnosis? Cross-sectional interview study. *BMJ Open*, 2012. **2**(6):e001977.
12. Hutchinson A, Barclay-Kling N, Galvin K, et al., Living with breathlessness: a systematic literature review and qualitative synthesis. *Eur Respir J*, 2018. **51**(2):1701477.
13. Chapple A, Ziebland S, McPherson A. Stigma, shame, and blame experienced by patients with lung cancer: qualitative study. *BMJ*, 2004. **328**(7454):1470.
14. Celli B, Blasi F, Gaga M, et al., Perception of symptoms and quality of life—comparison of patients' and physicians' views in the COPD MIRROR study. *Int J Chron Obstruct Pulmon Dis*, 2017. **12**:2189.
15. Hadjiphilippou S, Odogwu S-E, Dand P. Doctors' attitudes towards prescribing opioids for refractory dyspnoea: a single-centred study. *BMJ Support Palliat Care*, 2014. **4**(2): 190-192.
16. Currow DC, Abernethy AP, Ko DN. The active identification and management of chronic refractory breathlessness is a human right. *Thorax* 2014. **69**(4):393-94.
17. Başoğlu M. Effective management of breathlessness: a review of potential human rights issues. *Eur Respir J* 2017. **49**(5).